Buy Phenergan

What is the METRIC Study in Triple-Negative Breast Cancer?

METRIC Study Glemba CDX-011 in Metastatic gpNMB Triple-Negative Breast Cancer

You can help doctors evaluate an investigational medication as part of a medical research study for patients with triple-negative breast cancer.

Hundreds of thousands of women are diagnosed with breast cancer every year. Of these, about 15% will be diagnosed with triple-negative breast cancer. Unfortunately, for many of these women, available treatment options are not effective against their cancer or allow for continued growth of the cancer. This makes it critical to research additional treatment options for patients with triple-negative breast cancer.

Glembatumumab vedotin (CDX-011) is an investigational medication that targets a protein called gpNMB that is over-expressed in many cancers, including breast cancer. gpNMB is believed to be involved in cancer growth and the spread of cancer to other body parts (Rose, 2010). Glembatumumab vedotin has been studied in more than 250 patients with breast cancer and melanoma. The results of these studies support further testing, particularly in patients with triple-negative breast cancer (Press Release, 2013). Doctors are now conducting the METRIC Study to test the safety and effectiveness of glembatumumab vedotin in women who have triple-negative breast cancer that has spread (metastasized) to other parts of the body. If you have been diagnosed with triple-negative breast cancer that has spread beyond the original tumor, we hope that you will consider learning more about the METRIC Study.

Who can participate in the METRIC study?

To qualify for this study, you must:

  • Male or Female at least 18 years of age
  • Have been diagnosed with triple-negative breast cancer that has spread beyond the original tumor
  • Have gpNMB present in at least one tumor sample (tested as part of the study)
  • Have received standard therapies, including antracycline, if clinically indicated, and taxane treatments
  • Have received no more than 2 prior chemotherapy regimens for advanced breast cancer (cancer which has grown into surrounding tissues or beyond the original tumor). Treatment(s) given prior to the breast cancer becoming advanced is allowed. Talk to your doctor for details

There are other requirements that the study doctor and staff will review with you.

What happens during the METRIC study?

Before beginning the study, you will be evaluated for eligibility to participate. If you are eligible and you agree to participate, you will be randomly assigned to receive either glembatumumab vedotin or capecitabine, also known by the trade name Xeloda®. Capecitabine is approved by regulatory authorities for the treatment of breast cancer. You are twice as likely to receive glembatumumab vedotin as you are to receive capecitabine.

To find a study location near you, please visit clinicaltrials.gov.

   *Xeloda® is a registered trademark of Genentech, a member of the Roche group.

Volunteering for the METRIC Study in Triple-Negative Breast Cancer Over-expressing gpNMB

If you are interested in learning more about the METRIC study, please visit clinicaltrials.gov for a listing of study locations and their contact information. When you contact a study location, they will ask you some questions to see if you meet the basic criteria required to participate. If you do, they will set up an appointment for a more thorough screening and answer any questions you may have.

Choosing to participate in a study is an important personal decision. Before making a decision to pursue participation in a clinical trial, talk with your doctor or other health care professional, family, caregivers and friends.

If you are eligible for the trial and choose to participate, your health will be followed closely by a METRIC study doctor and you could make an important contribution to triple-negative breast cancer treatment research that may one day change the way the condition is treated.

Thank you for your interest in the METRIC Study for patients with triple-negative breast cancer over-expressing gpNMB.

To find a study location near you, please visit clinicaltrials.gov.